Previous 10 | Next 10 |
Pliant Therapeutics Inc. (PLRX) is expected to report $-0.78 for Q3 2023
2023-11-09 17:33:44 ET More on Pliant Therapeutics Pliant Therapeutics' Multi-Pronged Fibrosis Play In Therapeutics Space, I Prefer Vicore Pharma Over Pliant Therapeutics Biggest stock movers today: Sirius XM, United Natural Foods, Immunovant and more Pliant ...
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification Key Clinical Development and Regulatory appointments expand leadership team ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, presented three posters highlighting PLN-101095...
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced three presentations at the upco...
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking presentation of...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishi...
2023-09-26 14:31:26 ET Summary Pliant Therapeutics' bexotegrast shows multi-indicational promise, notably in primary sclerosing cholangitis, diversifying its asset utility beyond idiopathic pulmonary fibrosis. Financially, Pliant sustains a strong liquidity position with a 60-mont...
2023-09-26 12:10:03 ET Shares of clinical-stage biotech Pliant Therapeutics (NASDAQ: PLRX) were up more than 14% as of 11 a.m. ET on Tuesday after the company announced positive phase 2a trial information for its lead therapy. The stock is down more than 12% so far this year. ...
2023-09-26 10:00:07 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASDAQ: IMVT), Bullfrog AI (NASDAQ: B...
News, Short Squeeze, Breakout and More Instantly...
Pliant Therapeutics Inc. Company Name:
PLRX Stock Symbol:
NASDAQ Market:
Pliant Therapeutics Inc. Website:
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placebo Statistically significant ...
2024-06-14 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Boa...